The findings of a retrospective study corroborated the efficacy of topical resorcinol as sustained treatment in mild-to-moderate hidradenitis suppurativa manifestations compared to traditional clindamycin. Elisa Molinelli et al. aimed to compare the safety, effectiveness, and tolerability of long-term use of 15% topical resorcinol vs. 1% topical clindamycin in 134 people suffering from hidradenitis suppurativa.

Participants were randomly allocated to get topical clindamycin 1% (Group A, n=73) and topical resorcinol 15% (Group B, n=61). The clinical responses were compared at 12 weeks of treatment.

In comparison with clindamycin-treated people, resorcinol-treated people showed a remarkable improvement in pain Visual Analogue Scale (VAS) score, Hidradenitis Suppurativa Clinical Response (HiSCR), and International Hidradenitis Suppurativa Severity Score System (IHS4) from the baseline.

Hence, resorcinol in concentrations of 15% is a well-tolerated therapeutic choice that can be used as an alternative to clindamycin in people with hidradenitis suppurativa.